Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma

Open access
Lheureux, Stephanie, Butler, Marcus O., Clarke, Blaise, Cristea, Mihaela C., Martin, Lainie P., Tonkin, Katia, Fleming, Gini F., Tinker, Anna V., Hirte, Hal W., Tsoref, Daliah, Mackay, Helen, Dhani, Neesha C., Ghatage, Prafull, Weberpals, Johanne, Welch, Stephen, Pham, Nhu-An, Motta, Vinicius, Sotov, Valentin, Wang, Lisa, Karakasis, Katherine, Udagani, Smitha, Kamel-Reid, Suzanne, Streicher, Howard Z., Shaw, Patricia, Oza, Amit M. · 2018 · JAMA Oncology

Abstract

Importance: Based on evidence of human papillomavirus (HPV)-induced immune evasion, immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully humanized monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), which acts to downregulate the T-cell immune response. Objective: To assess the safety and antitumor activity of ipilimumab in recurrent cervical cancer. Design, Setting, and Participants: A multicenter trial was designed for patients with metastatic cervical cancer (squamous cell carcinoma or adenocarcinoma) with measurable disease and progression after at least 1 line of platinum chemotherapy. A run-in safety cohort using ipilimumab, 3 mg/kg, every 21 days for 4 cycles in 6 patients was followed by a phase II cohort of ipilimumab, 10 mg/kg, every 21 days for 4 cycles and then 4 cycles of maintenance therapy every 12 weeks for patients demonstrating radiologic response or stabilization. Immune correlative studies were performed on peripheral blood before and after therapy on archival tissue and fresh tumor obtained prior to registration and 7 days after cycle 2. The study was conducted from December 3, 2012, to September 15, 2014. The data were analyzed from April 2016 to June 2016 and in July 2017. Main Outcomes and Measures: The primary end points were safety and objective response rate. Immune analyses were performed on blood and tumor tissue. Results: A total of 42 women (median age, 49 years; range, 23-78 years) were enrolled (29 [69%] squamous cell cervical cancer and 13 [31%] adenocarcinoma; 37 [93%] of 40 patients with tissue available for analysis had HPV-positive confirmation; there was no archival tissue for 2 women). Grade 3 toxic effects included diarrhea in 4 patients, 3 of whom had colitis. Of 34 patients evaluated for best response (Response Evaluation Criteria in Solid Tumors, version 1.1), 1 patient had partial response and 10 had stable disease. The median progression-free survival and overall survival were 2.5 months (95% CI, 2.1-3.2 months) and 8.5 months (95% CI, 3.6-not reached; 1 patient was still alive), respectively. Intratumoral pretreatment CD3, CD4, CD8, FoxP3, indoleamine 2,3-dioxygenase, and programmed cell death ligand 1 (PD-L1) expression was not predictive of benefit and did not significantly change with treatment. Multicolor flow cytometry on peripheral lymphocytes revealed a treatment-dependent increase of inducible T-cell costimulator, human leukocyte antigen-antigen D related, and PD-1 during initial treatment, which returned to baseline during maintenance. Conclusions and Relevance: Ipilimumab was tolerable in this population but did not show significant single-agent activity. Immune changes were induced by anti-CTLA-4 therapy but did not correlate with clinical activity. Changes in these markers may guide further treatment strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2017.3776

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Ipilimumab and Its Toxicities: A Multidisciplinary Approach

    Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320 · cited 1×

    “(%) All Grades Grade ≥3 Diarrhea 12 (29) 4 (33) Colitis 2 (5) 1 (50) Enterocolitis 1 (2) 1 (100) Pancolitis 1 (2) 1 (100) Colonic perforation 1 (2) 1 (100) Maculopapular rash 12 (29) 1 (8) Pruritus 9 (21) 1 (11) Increased aspartate aminotransferase 9 (21) 1 (11) Increased alanine aminotransferase 9 (21) 0 Arthralgia 3…”

Show all 1 references

Cited by

See all 160

Metadata

Authors
Lheureux, S., Butler, M. O., Clarke, B., Cristea, M. C., Martin, L. P., Tonkin, K., Fleming, G. F., Tinker, A. V., Hirte, H. W., Tsoref, D., Mackay, H., Dhani, N. C., Ghatage, P., Weberpals, J., Welch, S., Pham, N.-A., Motta, V., Sotov, V., Wang, L., Karakasis, K., Udagani, S., Kamel-Reid, S., Streicher, H. Z., Shaw, P., & Oza, A. M.
Venue
JAMA Oncology
Published
2018-07-12
Volume
4
Issue
7
Pages
e173776
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2770798942
Cited by
160
References
1
FWCI
5.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma. https://app.cochat.ai/papers/10.1001/jamaoncol.2017.3776
The paper
Lheureux, S., Butler, M. O., Clarke, B., Cristea, M. C., Martin, L. P., Tonkin, K., Fleming, G. F., Tinker, A. V., Hirte, H. W., Tsoref, D., Mackay, H., Dhani, N. C., Ghatage, P., Weberpals, J., Welch, S., Pham, N.-A., Motta, V., Sotov, V., Wang, L., . . . Oza, A. M. (2018). Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2017.3776

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.